Skip to main content
CCTI Research

CCTI Research

The Center for Clinical Trials Innovation focuses on making trials more efficient, practical, and better aligned with the needs of patients, clinicians, and health systems.

Key Research Themes

Innovative Trial Designs

  • Pragmatic cluster-randomized trials

    • Stepped-wedge, crossover trials, factorial, and supplement designs

    • Methods for sample size calculation and power optimization for complex trials

    • Strategies for optimal sequence generation and allocation

  • Bayesian platform trials and adaptive designs

  • Registry-based randomized controlled trials

  • Type 1, 2 and 3, hybrid effectiveness-implementation designs

Statistical Innovation and Trial Analytics

  • Causal inference methods to maximally learn from RCTs

    • Mediation analysis for mechanism evaluation

    • Principal stratification frameworks for dropout, non-adherence, and noncompliance

  • Analytical approaches to handle period effects and carryover effects

  • Optimal approaches to analyze interactions and main effects

  • Strategic covariate adjustment for increased statistical power

Machine Learning and AI for Precision Trials

  • AI, Bayesian, and machine learning methods for treatment effect heterogeneity exploration

    • Causal machine learning for subgroup identification

    • Bayesian causal and additive regression trees and samplers

    • Targeted learning approaches for personalized treatment effects

  • Predictive analytics for trial optimization

  • Patient recruitment and site selection algorithms

  • Dropout prediction and mitigation strategies

  • Adaptive enrichment based on predicted treatment response

  • Natural language processing for outcome extraction

Outcome Measure Development and Validation

  • Patient-centered outcome development

  • Statistical derivation and evaluation of composite outcomes

  • Defining clinically meaningful estimands

Learn About Our Innovative Methodologic Research

Key publications showcasing CCTI’s innovative methods and research contributions.

Bayesian Statistics for Clinical Research

Abstract: Frequentist and Bayesian statistics represent two differing paradigms for the analysis of data. Frequentism became the dominant mode of statistical thinking in medical practice during the 20th century. The advent of modern computing has made Bayesian analysis increasingly accessible, enabling growing use of Bayesian methods in a range of disciplines, including medical research. Rather than conceiving of probability as the expected frequency of an event (purported to be measurable and objective), Bayesian thinking conceives of probability as a measure of strength of belief (an explicitly subjective concept). Bayesian analysis combines previous information (represented by a mathematical probability distribution, the prior) with information from the study (the likelihood function) to generate an updated probability distribution (the posterior) representing the information available for clinical decision making. Owing to its fundamentally different conception of probability, Bayesian statistics offers an intuitive, flexible, and informative approach that facilitates the design, analysis, and interpretation of clinical trials. In this Review, we provide a brief account of the philosophical and methodological differences between Bayesian and frequentist approaches and survey the use of Bayesian methods for the design and analysis of clinical research.

Analysis of Cohort Stepped Wedge Cluster-Randomized Trials With Nonignorable Dropout via Joint Modeling

Abstract: Stepped wedge cluster-randomized trial (CRTs) designs randomize clusters of individuals to intervention sequences, ensuring that every cluster eventually transitions from a control period to receive the intervention under study by the end of the study period. The analysis of stepped wedge CRTs is usually more complex than parallel-arm CRTs due to more complex intra-cluster correlation structures. A further challenge in the analysis of closed-cohort stepped wedge CRTs, which follow groups of individuals enrolled in each period longitudinally, is the occurrence of dropout. This is particularly problematic in studies of individuals at high risk for mortality, which causes nonignorable missing outcomes. If not appropriately addressed, missing outcomes from death will erode statistical power, at best, and bias treatment effect estimates, at worst. Joint longitudinal-survival models can accommodate informative dropout and missingness patterns in longitudinal studies. Specifically, within the joint longitudinal-survival modeling framework, one directly models the dropout process via a time-to-event submodel together with the longitudinal outcome of interest. The two submodels are then linked using a variety of possible association structures. This work extends linear mixed-effects models by jointly modeling the dropout process to accommodate informative missing outcome data in closed-cohort stepped wedge CRTs. We focus on constant intervention and general time-on-treatment effect parametrizations for the longitudinal submodel and study the performance of the proposed methodology using Monte Carlo simulation under several data-generating scenarios. We illustrate the joint modeling methodology in practice by reanalyzing data from the “Frail Older Adults: Care in Transition” (ACT) trial, a stepped wedge CRT of a multifaceted geriatric care model versus usual care in 35 primary care practices in the Netherlands.

Assessing Treatment Effect Heterogeneity in the Presence of Missing Effect Modifier Data in Cluster-Randomized Trials

Abstract: Understanding whether and how treatment effects vary across subgroups is crucial to inform clinical practice and recommendations. Accordingly, the assessment of heterogeneous treatment effects based on pre-specified potential effect modifiers has become a common goal in modern randomized trials. However, when one or more potential effect modifiers are missing, complete-case analysis may lead to bias and under-coverage. While statistical methods for handling missing data have been proposed and compared for individually randomized trials with missing effect modifier data, few guidelines exist for the cluster-randomized setting, where intracluster correlations in the effect modifiers, outcomes, or even missingness mechanisms may introduce further threats to accurate assessment of heterogeneous treatment effect. In this article, the performance of several missing data methods are compared through a simulation study of cluster-randomized trials with continuous outcome and missing binary effect modifier data, and further illustrated using real data from the Work, Family, and Health Study. Our results suggest that multilevel multiple imputation and Bayesian multilevel multiple imputation have better performance than other available methods, and that Bayesian multilevel multiple imputation has lower bias and closer to nominal coverage than standard multilevel multiple imputation when there are model specification or compatibility issues.

A Bayesian Machine Learning Approach for Estimating Heterogeneous Survivor Causal Effects: Applications to a Critical Care Trial

Abstract: Assessing heterogeneity in the effects of treatments has become increasingly popular in the field of causal inference and carries important implications for clinical decision-making. While extensive literature exists for studying treatment effect heterogeneity when outcomes are fully observed, there has been limited development in tools for estimating heterogeneous causal effects when patient-centered outcomes are truncated by a terminal event, such as death. Due to mortality occurring during study follow-up, the outcomes of interest are unobservable, undefined, or not fully observed for many participants in which case principal stratification is an appealing framework to draw valid causal conclusions. Motivated by the Acute Respiratory Distress Syndrome Network (ARDSNetwork) ARDS respiratory management (ARMA) trial, we developed a flexible Bayesian machine learning approach to estimate the average causal effect and heterogeneous causal effects among the always-survivors stratum when clinical outcomes are subject to truncation. We adopted Bayesian additive regression trees (BART) to flexibly specify separate mean models for the potential outcomes and latent stratum membership. In the analysis of the ARMA trial, we found that the low tidal volume treatment had an overall benefit for participants sustaining acute lung injuries on the outcome of time to returning home but substantial heterogeneity in treatment effects among the always-survivors, driven most strongly by biologic sex and the alveolar-arterial oxygen gradient at baseline (a physiologic measure of lung function and degree of hypoxemia). These findings illustrate how the proposed methodology could guide the prognostic enrichment of future trials in the field.

A Bayesian Approach for Estimating the Survivor Average Causal Effect When Outcomes Are Truncated by Death in Cluster-Randomized Trials

Abstract: Many studies encounter clustering due to multicenter enrollment and nonmortality outcomes, such as quality of life, that are truncated due to death—that is, missing not at random and nonignorable. Traditional missing-data methods and target causal estimands are suboptimal for statistical inference in the presence of these combined issues, which are especially common in multicenter studies and cluster-randomized trials (CRTs) carried out among the elderly or seriously ill. Using principal stratification, we developed a Bayesian estimator that jointly identifies the always-survivor principal stratum in a clustered/hierarchical data setting and estimates the average treatment effect among them (i.e., the survivor average causal effect (SACE)). In simulations, we observed low bias and good coverage with our method. In a motivating CRT, the SACE and the estimate from complete-case analysis differed in magnitude, but both were small, and neither was incompatible with a null effect. However, the SACE estimate has a clear causal interpretation. The option to assess the rigorously defined SACE estimand in studies with informative truncation and clustering can provide additional insight into an important subset of study participants. Based on the simulation study and CRT reanalysis, we provide practical recommendations for using the SACE in CRTs and software code to support future research.

Learn About the Randomized Trials We Design and Support

Discover important publications and key insights from the randomized trials designed and supported by CCTI.

Peer and Patient Feedback to Increase Adherence to Postoperative Opioid Prescribing Guidelines: A Stepped-Wedge Cluster Randomized Clinical Trial

Question: Can providing peer prescribing comparisons and patient-reported outcomes related to pain increase surgical clinician adherence to opioid prescribing guidelines?

Findings: In this stepped-wedge cluster randomized clinical trial that included 143 surgical clinicians treating 20 557 patients, the proportion of guideline-adherent prescriptions increased during the intervention period from 57.2% to 71.8%, with an adjusted absolute difference of 5.3%, while patients’ reported ability to manage pain remained unchanged.

Meaning: Normative and patient feedback can encourage surgical clinicians to write prescriptions that abide by opioid prescribing guidelines while maintaining patients’ ability to manage pain.

Nudging Clinicians to Promote Serious Illness Communication for Critically Ill Patients: A Pragmatic Cluster Randomized Trial

Question: Does nudging intensive care unit (ICU) clinicians to adhere to communication guidelines improve clinical outcomes?

Findings: This pragmatic trial involving 3500 encounters among adults with a chronic serious illness and at least 48 hours of mechanical ventilation in 17 ICUs (February 2018-October 2020) found that nudging clinicians to document prognosis, whether a comfort-focused treatment alternative was offered or not, did not significantly reduce hospital length of stay. The comfort-focused treatment alternative nudge led to a significant increase in discharge to hospice (10.9% vs 7.3%) and earlier comfort-care orders (4.5 days vs 3.6 days), without significantly affecting hospital or long-term mortality.

Meaning: Nudging ICU clinicians to adhere to communication guidelines did not reduce length of stay, but the treatment alternative nudge improved certain secondary end-of-life care processes among critically ill patients with limited prognoses.

Default Palliative Care Consultation for Seriously Ill Hospitalized Patients: A Pragmatic Cluster Randomized Trial

Question: Does ordering palliative care by default (allowing opt-out) increase consultation and improve clinical outcomes?

Findings: In this pragmatic trial conducted from March 2016 to November 2018 among 24 065 inpatients 65 years or older with advanced chronic obstructive pulmonary disease, dementia, or kidney disease, default orders for palliative care did not significantly reduce length of stay. Default orders significantly increased consultation rate compared with usual care (43.9% vs 16.6%), decreased time to consultation by 1.2 days, and increased odds of hospice discharge and do-not-resuscitate orders at discharge.

Meaning  Default palliative care consult orders did not reduce length of stay for older inpatients with advanced chronic illnesses, but improved the rate and timing of consultation and some end-of-life care processes.

Norepinephrine Versus Phenylephrine for Treating Hypotension During General Anaesthesia in Adult Patients Undergoing Major Noncardiac Surgery: A Multicentre, Open-Label, Cluster-Randomised, Crossover, Feasibility, and Pilot Trial

Background: Intraoperative hypotension is associated with postoperative complications. The use of vasopressors is often required to correct hypotension but the best vasopressor is unknown.

Methods: A multicentre, cluster-randomised, crossover, feasibility and pilot trial was conducted across five hospitals in California. Phenylephrine (PE) vs norepinephrine (NE) infusion as the first-line vasopressor in patients under general anaesthesia alternated monthly at each hospital for 6 months. The primary endpoint was first-line vasopressor administration compliance of 80% or higher. Secondary endpoints were acute kidney injury (AKI), 30-day mortality, myocardial injury after noncardiac surgery (MINS), hospital length of stay, and rehospitalisation within 30 days.

Results: A total of 3626 patients were enrolled over 6 months; 1809 patients were randomised in the NE group, 1817 in the PE group. Overall, 88.2% received the assigned first-line vasopressor. No drug infiltrations requiring treatment were reported in either group. Patients were median 63 yr old, 50% female, and 58% white. Randomisation in the NE group vs PE group did not reduce readmission within 30 days (adjusted odds ratio=0.92; 95% confidence interval, 0.6–1.39), 30-day mortality (1.01; 0.48–2.09), AKI (1.1; 0.92–1.31), or MINS (1.63; 0.84–3.16).

Conclusions: A large and diverse population undergoing major surgery under general anaesthesia was successfully enrolled and randomised to receive NE or PE infusion. This pilot and feasibility trial was not powered for adverse postoperative outcomes and a follow-up multicentre effectiveness trial is planned.